If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 10 [...]

Poniard Pharmaceuticals, Inc. (NASDAQ: PARDD) today announced that its planned merger with Allozyne has been terminated. A condition of the merger was that it would qualify for listing on The Nasdaq Capital Market, which requires a share price of at least $4. It is currently trading at $2.95 despite effecting a 1:40 reverse split last month. [...]

On August 1, 2011, I listed seven companies facing NASDAQ delist or a reverse split to remain listed on NASDAQ. I now follow up the list by firstly noting my prediction, then what actually happened. You can read the original post HERE and results of other projections HERE. (First bracket indicates price as of August [...]

VIVUS, Inc. (NASDAQ: VVUS) today announced topline preliminary results from its FORTRESS study. The study was a retrospective  study of existing electronic healthcare databases to assess fetal outcomes, in the offspring of women who were exposed to topiramate during the first trimester of pregnancy. The study was conducted as part of the Qnexa NDA for obesity. The study showed that [...]

Repligen Corporation (NASDAQ: RGEN) said that it has submitted its NDA for SecreFlo (RG1068) for pancreatic imaging in patients with pancreatitis. A 6-month priority review was requested. Impax Pharmaceuticals (NASDAQ: IPXL) also announced the submission of its NDA for IPX066  for the treatment of idiopathic Parkinson’s disease (PD). Raptor Pharmaceutical Corp.  (Nasdaq:RPTP) maintained previous guidance that it expects to [...]

Santarus, Inc. (NASDAQ: SNTS) announced that it submitted a New Drug Application (NDA) for UCERIS (budesonide) Tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis. UCERIS is being developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. The company had been aiming for some time to file the [...]

Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) mentioned last month that the FDA indicated its intent to discuss the Northera NDA at a February 2012 meeting of its Cardiovascular and Renal Drugs Advisory Committee.  A tentative schedule of all 2012 meetings was released today with the above mentioned committee to meet on February 23. VIVUS, Inc. (NASDAQ: VVUS) [...]

See individual posts made in the last week for more detail. PDUFA/FDA RELATED EVENTS NeurogesX, Inc. (Nasdaq:NGSX) will meet with the FDA Anesthetic and Analgesic Drug Products Advisory Committee on February 9, 2012 to discuss the available efficacy and safety data for sNDA of QUTENZA for the management of neuropathic pain related to HIV-associated peripheral neuropathy. Isis Pharmaceuticals, [...]